My grandfather told me a story once about his older brother, who died in 1938 at the age of nineteen from a scratch on his hand that became infected. A scratch. The infection spread to his blood — septicemia, they called it — and there was nothing to be done. Antibiotics existed in theory — Alexander Fleming had discovered penicillin a decade earlier — but mass production would not begin for another five years. His brother died of what would today be a trivial injury, treated with a few days of oral antibiotics and perhaps a bandage change.
I think about that story often, because we are living through an era in which its relevance is shifting from historical curiosity to potential preview. Antimicrobial resistance — the ability of bacteria, viruses, fungi, and parasites to survive the drugs designed to kill them — is advancing at a pace that threatens to return us to a world where minor infections become lethal, routine surgeries become dangerous, and the entire edifice of modern medicine, which depends on the ability to control infection, begins to crumble.
This is not speculative. It is happening now.
The scale of the crisis
In 2019, a comprehensive analysis published in The Lancet — the most rigorous assessment of antimicrobial resistance (AMR) ever conducted — estimated that bacterial AMR was directly responsible for 1.27 million deaths worldwide and was associated with 4.95 million deaths in total (Murray et al., 2022). To put this in context: 1.27 million direct deaths exceeds the toll of HIV/AIDS (860,000) and malaria (640,000). AMR is already one of the leading causes of death globally, and most people have never heard this statistic.
In the United States alone, the CDC estimates that at least 2.8 million antibiotic-resistant infections occur annually, resulting in approximately 35,000 deaths (CDC, 2019). These figures are almost certainly underestimates, because AMR is frequently not recorded as a cause of death and many resistant infections go undetected or unreported.
The trajectory is even more alarming than the current numbers. A commissioned review led by economist Jim O'Neill projected that if current trends continue, AMR could cause 10 million deaths annually by 2050 — surpassing cancer as a cause of death and reducing global GDP by 2-3.5% (O'Neill, 2016). The economic cost was estimated at $100 trillion in cumulative lost output. These projections contain significant uncertainty, but even conservative scenarios describe a public health catastrophe of historic proportions.
How resistance develops
Antibiotic resistance is a natural evolutionary phenomenon. Bacteria have been competing with antimicrobial compounds for billions of years — the soil bacterium Streptomyces, which produces many of the antibiotics we use clinically, has been engaged in chemical warfare with competing organisms since long before humans existed. Resistance genes are ancient, diverse, and already present in bacterial populations throughout the natural environment (D'Costa et al., 2011).
What human antibiotic use has done is dramatically accelerate the selection pressure driving resistance. Every time an antibiotic is used — whether in a hospital, a doctor's office, or a farm — it kills susceptible bacteria while leaving resistant organisms to survive and reproduce. This is Darwinian natural selection operating in real time, on populations that can double every twenty minutes. The more antibiotics are used, the faster resistance spreads.
The mechanisms of resistance are diverse and, from a purely scientific perspective, elegant. Bacteria can resist antibiotics by: enzymatic degradation (producing enzymes like beta-lactamases that destroy the antibiotic molecule); target modification (altering the molecular structure the antibiotic targets so it no longer binds effectively); efflux pumps (actively pumping the antibiotic out of the cell before it can take effect); membrane impermeability (modifying the cell wall to prevent the antibiotic from entering); and metabolic bypass (developing alternative metabolic pathways that circumvent the inhibited process) (Blair et al., 2015).
Crucially, bacteria can acquire resistance not only through mutation but through horizontal gene transfer — the direct exchange of genetic material between bacteria, even between different species. This means that a resistance gene that evolves in a harmless environmental bacterium can be transferred to a dangerous pathogen, conferring resistance without that pathogen having ever been directly exposed to the antibiotic. Resistance genes travel on mobile genetic elements — plasmids, transposons, integrons — that function as molecular vehicles for the rapid dissemination of resistance across bacterial populations (von Wintersdorff et al., 2016).
The ESKAPE pathogens
Six bacterial species have been identified as particularly dangerous due to their combination of virulence, clinical importance, and resistance profiles. Known collectively as the ESKAPE pathogens — Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species — these organisms are responsible for the majority of hospital-acquired infections and are increasingly resistant to last-line antibiotics (Rice, 2008).
Methicillin-resistant Staphylococcus aureus (MRSA), perhaps the most widely recognized resistant pathogen, causes an estimated 80,000 invasive infections and 11,000 deaths annually in the United States (CDC, 2019). Once confined to hospitals, community-associated MRSA now causes skin infections, pneumonia, and bloodstream infections in otherwise healthy individuals with no healthcare exposure.
Carbapenem-resistant Enterobacteriaceae (CRE) — dubbed "nightmare bacteria" by the CDC — are resistant to carbapenems, which are among the last antibiotics effective against gram-negative bacteria. CRE infections carry mortality rates of 40-50%, and treatment options are limited to a handful of newer agents that are expensive, often toxic, and already facing emerging resistance (van Duin & Doi, 2017).
The agricultural dimension
Human clinical use accounts for only a fraction of global antibiotic consumption. Approximately 73% of all antibiotics sold globally are used in livestock production, primarily not to treat infections but to promote growth and prevent disease in crowded, unsanitary farming conditions (Van Boeckel et al., 2019). This represents an enormous, ongoing selection pressure for resistance that operates largely outside the clinical domain.
The mechanism by which agricultural antibiotic use drives clinical resistance is well-documented. Resistant bacteria from animal operations enter the human population through multiple pathways: direct contact with animals, contamination of meat products, environmental dissemination through manure application and water runoff, and airborne transmission from concentrated animal feeding operations (CAFOs). A study published in Science demonstrated that the same resistance genes found in livestock bacteria were subsequently detected in human clinical isolates, with genomic evidence of direct transmission (Mathers et al., 2015).
The European Union banned the use of antibiotics as growth promoters in livestock in 2006. Denmark, which pioneered voluntary elimination of growth-promoting antibiotics in the 1990s, demonstrated that such restrictions could be implemented without significant economic harm to the agricultural industry — antibiotic use decreased by more than 50% while productivity remained stable (Aarestrup et al., 2010). The United States did not implement comparable restrictions until 2017, when the FDA's Veterinary Feed Directive required veterinary oversight for medically important antibiotics used in feed and water — a necessary step, but one that critics argue does not go far enough, as antibiotics can still be used routinely for disease prevention in intensive farming operations.
The broken pipeline
If resistance is advancing, why aren't new antibiotics being developed to replace the drugs that are losing effectiveness? The answer reveals one of the most consequential market failures in modern medicine.
Antibiotic drug development has collapsed. Between 1980 and 2000, the FDA approved an average of three new antibiotic classes per decade. Since 2000, only two novel antibiotic classes have reached the market (Silver, 2011). Of the 18 largest pharmaceutical companies, 15 have abandoned antibiotic research entirely. The pipeline that remains is thin, fragile, and concentrated among small biotechnology companies with limited resources and high failure rates.
The economic explanation is brutally simple. Antibiotics are, from a pharmaceutical business perspective, terrible products. They are used for short courses (days to weeks), unlike chronic disease medications that are taken for years or decades. New antibiotics, when they are developed, are deliberately held in reserve as drugs of last resort — meaning they generate minimal revenue while they sit on the shelf waiting for resistance to render older drugs ineffective. And the market dynamics penalize success: an effective antibiotic that cures an infection eliminates its own demand (Outterson et al., 2015).
A study in Clinical Infectious Diseases estimated that the net present value of a new antibiotic — accounting for development costs, regulatory timelines, market size, and pricing — was approximately negative $50 million, making antibiotic development one of the least profitable pharmaceutical investments available (Årdal et al., 2020). Several companies that successfully brought new antibiotics to market have subsequently gone bankrupt, including Achaogen (which developed plazomicin) and Melinta Therapeutics (which developed vabomere and delafloxacin). The market rewards the drugs we need least and punishes the drugs we need most.
The pull incentive models
Recognizing the market failure, policymakers have proposed "pull incentive" models designed to delink antibiotic revenue from sales volume. The most prominent is the subscription or "Netflix" model, in which governments pay a fixed annual fee for access to new antibiotics regardless of how many units are actually dispensed. The UK piloted this model in 2022 with two antibiotics — ceftazidime-avibactam and cefiderocol — paying fixed annual fees of £10 million each for guaranteed access (Gotham et al., 2021).
The PASTEUR Act, proposed in the US Congress, would create a subscription-style payment system providing contracts of up to $3 billion each for critical-need antibiotics. As of this writing, the legislation has not been enacted, though it has bipartisan support and endorsement from major medical organizations. The fundamental challenge is political: investing billions in drugs that may not be widely used for years requires a long-term perspective that is structurally difficult for legislative processes organized around two- and four-year election cycles.
The stewardship imperative
In the absence of new antibiotics, the most important strategy for managing resistance is antibiotic stewardship — the systematic effort to optimize antibiotic use, ensuring that antibiotics are prescribed only when necessary, at the correct dose, for the correct duration, and targeting the correct pathogen.
The scale of inappropriate antibiotic use is staggering. A study published in the BMJ analyzed outpatient antibiotic prescriptions in the United States and found that approximately 30% of all antibiotic prescriptions were unnecessary — the majority prescribed for viral respiratory infections against which antibiotics have no effect (Fleming-Dutra et al., 2016). This translates to approximately 47 million unnecessary prescriptions annually — 47 million selection events driving resistance without providing any clinical benefit.
Hospital stewardship programs have demonstrated significant impact. A systematic review published in The Lancet Infectious Diseases found that antibiotic stewardship programs reduced antibiotic consumption by a median of 22%, decreased Clostridioides difficile infections by 32%, and reduced antibiotic-resistant infections by 18% — without adversely affecting clinical outcomes (Baur et al., 2017). These are substantial gains achievable through organizational change rather than technological innovation.
But stewardship faces structural obstacles. Outpatient prescribing — which accounts for approximately 80% of human antibiotic use — is far more difficult to regulate than hospital prescribing. Physicians face patient demand for antibiotics (studies show that patients prescribed antibiotics for viral infections rate their physicians more highly on satisfaction surveys), time pressure that discourages the detailed explanations required to decline antibiotic requests, and diagnostic uncertainty that favors empiric treatment over watchful waiting (Mangione-Smith et al., 2006).
The diagnostic gap
One of the most significant barriers to appropriate antibiotic use is the inability to rapidly distinguish bacterial from viral infections at the point of care. Most antibiotic prescribing decisions are made clinically — based on symptoms, physical examination, and clinical judgment — without definitive microbiological diagnosis. Current bacterial culture methods require 24-72 hours to identify the pathogen and determine its susceptibility profile. By the time results are available, the patient has already been started on empiric therapy — often a broad-spectrum antibiotic that is effective but drives resistance more aggressively than a narrow-spectrum alternative would.
Rapid molecular diagnostics — technologies that can identify pathogens and resistance genes directly from clinical specimens in minutes to hours — have the potential to transform antibiotic prescribing. PCR-based platforms, mass spectrometry, and next-generation sequencing are increasingly available in hospital settings, and point-of-care tests for specific pathogens (influenza, strep, RSV) have been available in outpatient settings for years.
But adoption remains limited. A survey published in Clinical Microbiology Reviews found that fewer than 20% of hospitals had implemented rapid molecular diagnostics for bloodstream infections, and fewer than 5% of outpatient practices used point-of-care tests to guide antibiotic prescribing for respiratory infections (Caliendo et al., 2013). Cost, workflow integration, and reimbursement barriers remain significant obstacles. And even when rapid diagnostics are available, studies show that their impact on prescribing behavior is limited unless paired with active stewardship programs that support clinicians in acting on the information (Timbrook et al., 2017).
The innovation frontier
While the antibiotic pipeline has thinned, alternative approaches to treating bacterial infections are receiving increasing scientific attention — though none have yet reached the clinical maturity required to serve as reliable antibiotic replacements.
Bacteriophage therapy — using viruses that specifically infect and kill bacteria — is the most developed alternative. Phage therapy was widely used in the former Soviet Union and Eastern Europe throughout the twentieth century and is experiencing a renaissance driven by the AMR crisis. Individual case reports have described dramatic recoveries in patients with extensively drug-resistant infections treated with personalized phage cocktails (Schooley et al., 2017). However, regulatory frameworks for phage therapy remain undeveloped in Western countries, large randomized controlled trials are lacking, and the need for individualized phage selection complicates scalable manufacturing.
Antibody-based therapies target specific bacterial virulence factors or toxins rather than killing bacteria directly. Bezlotoxumab, an anti-toxin B antibody approved for prevention of recurrent C. difficile infection, represents a proof of concept. But antibody therapies are expensive to manufacture, narrow in spectrum, and cannot replace broad-spectrum antibiotics for empiric treatment.
Microbiome restoration approaches recognize that the gut microbiome itself provides colonization resistance — protection against pathogenic organisms. Fecal microbiota transplantation (FMT) has demonstrated remarkable efficacy for recurrent C. difficile infection. More refined approaches, using defined consortia of beneficial bacteria rather than whole fecal material, are in clinical development for both C. difficile and multidrug-resistant organism decolonization.
Antimicrobial peptides — small proteins produced by virtually all living organisms as part of innate immunity — represent another avenue of investigation. These molecules have broad-spectrum activity and are less prone to resistance development than conventional antibiotics, though challenges in stability, toxicity, and manufacturing cost have limited clinical translation.
What you need to know
The antibiotic resistance crisis is not a problem that individual behavior changes can solve — it requires coordinated action across healthcare, agriculture, pharmaceutical development, and public policy. But there are things you can do:
Never pressure your physician for antibiotics. If your doctor determines that your infection is viral — as most respiratory infections are — antibiotics will not help and will contribute to resistance. Trust the clinical judgment.
Complete prescribed courses. When antibiotics are appropriately prescribed, take them as directed. Incomplete courses may fail to eliminate the infection while selecting for partially resistant organisms. (Note: recent evidence has challenged the traditional "always finish the course" dogma, and physicians may increasingly prescribe shorter courses — follow your physician's specific guidance, which may differ from historical advice.)
Practice infection prevention. Handwashing, vaccination, food safety, and wound care reduce the need for antibiotics in the first place.
Support policy change. The structural problems driving AMR — agricultural overuse, broken R&D economics, inadequate stewardship infrastructure, insufficient diagnostics — require political solutions. Supporting legislation like the PASTEUR Act and advocating for restrictions on agricultural antibiotic use are among the most impactful things individual citizens can do.
The era of antibiotics is not over. But the era of taking antibiotics for granted — of assuming that bacterial infections are always treatable, that surgery is always safe from infectious complications, that a scratch on the hand is always trivial — that era is ending. What comes next depends on choices being made now, by policymakers, physicians, farmers, pharmaceutical executives, and patients. The stakes could not be higher.
References
- Aarestrup, F. M., et al. (2010). Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrobial Agents and Chemotherapy, 45(7), 2054–2059.
- Årdal, C., et al. (2020). Antibiotic development — economic, regulatory and societal challenges. Nature Reviews Microbiology, 18(5), 267–274.
- Baur, D., et al. (2017). Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria. The Lancet Infectious Diseases, 17(9), 990–1001.
- Blair, J. M., et al. (2015). Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology, 13(1), 42–51.
- Caliendo, A. M., et al. (2013). Better tests, better care: Improved diagnostics for infectious diseases. Clinical Infectious Diseases, 57(suppl 3), S139–S170.
- CDC. (2019). Antibiotic Resistance Threats in the United States. Centers for Disease Control and Prevention.
- D'Costa, V. M., et al. (2011). Antibiotic resistance is ancient. Nature, 477(7365), 457–461.
- Fleming-Dutra, K. E., et al. (2016). Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits. JAMA, 315(17), 1864–1873.
- Gotham, D., et al. (2021). Reimbursement models to tackle market failures for antimicrobials. Health Policy, 125(3), 296–306.
- Mangione-Smith, R., et al. (2006). Communication practices and antibiotic use for acute respiratory tract infections. Annals of Family Medicine, 4(2), 105–113.
- Mathers, A. J., et al. (2015). Molecular dissection of an outbreak of carbapenem-resistant Enterobacteriaceae. PNAS, 112(44), 13574–13579.
- Murray, C. J., et al. (2022). Global burden of bacterial antimicrobial resistance in 2019. The Lancet, 399(10325), 629–655.
- O'Neill, J. (2016). Tackling Drug-Resistant Infections Globally. Review on Antimicrobial Resistance.
- Outterson, K., et al. (2015). Repairing the broken market for antibiotic innovation. Health Affairs, 34(2), 277–285.
- Rice, L. B. (2008). Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. Journal of Infectious Diseases, 197(8), 1079–1081.
- Schooley, R. T., et al. (2017). Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrobial Agents and Chemotherapy, 61(10), e00954-17.
- Silver, L. L. (2011). Challenges of antibacterial discovery. Clinical Microbiology Reviews, 24(1), 71–109.
- Timbrook, T. T., et al. (2017). The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections. Clinical Infectious Diseases, 64(1), 15–23.
- Van Boeckel, T. P., et al. (2019). Global trends in antimicrobial resistance in animals in low- and middle-income countries. Science, 365(6459), eaaw1944.
- van Duin, D., & Doi, Y. (2017). The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence, 8(4), 460–469.
- von Wintersdorff, C. J., et al. (2016). Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. Frontiers in Microbiology, 7, 173.